---
title: 'Quality (QA) Lead - CDMO at Mytos'
canonical: 'https://feeny.ai/job/quality-qa-lead-cdmo-mytos-london-hvpy6dwzm2e1'
type: 'job'
last_seen: '2026-09-07'
---

# Quality (QA) Lead - CDMO at Mytos

- **Company:** Mytos
- **Location:** London, United Kingdom
- **Employment:** full-time
- **Work type:** onsite
- **Posted:** 2025-11-28
- **Last confirmed live:** 2026-09-07
- **Apply:** https://jobs.lever.co/mytos/98eb57ab-c6c1-4b48-a317-3be17e27cee9

## Job description

## About Us

You rarely get the chance to change an entire industry. But that's the position we find ourselves in. Join us, and you’ll help scale cures to patients that need them sooner.

We’ve developed fully-automated cell manufacturing sites powered by custom robotics - to scale therapies to millions of patients. Last year, patients were cured of diseases like Parkinson’s and vision loss using stem-cell derived cells - but today these Regenerative Medicines are produced by hand, meaning they’re too expensive and hard to scale. With our automated CDMO, these therapies can now be scaled globally at low cost.

We've announced partnerships across multiple therapies so far ranging from Parkinson’s, to hearing loss, to bone repair - and raised $24m to expand into the market faster, and accelerate our development! Within the next 12-18 months, neurons grown on our machines will be going into Parkinson’s patient brains.

We’ve assembled a world-class team to take on this challenge, with ex-Dyson engineers and Nature-published scientists working hand-in-hand. You can learn more about your potential Mytos teammates here: Team

Mytos is backed by Y Combinator, the most successful startup program in the world which produced companies such as AirBnb, Dropbox, and Ginkgo Bioworks.

## The Role

We’re looking for an ambitious and pragmatic Quality Assurance Lead to work with leadership to ensure quality moves in hand in hand with business vision. You’ll work on moving us fast towards our MHRA Manufacturing and Import Authorisation (MIA) license for our first site. You’ll get to collaborate with our advisors, such as former VP Quality for Cell and Gene Therapy at Catalent, and the former CTO of Regenerative Medicine at Resilience. This is a unique opportunity to establish quality at the world’s first automated CDMO for Regenerative Medicine.

What you'll be doing:

- Lead Mytos an MHRA MIA(IMP) license for our the first site as fast as possible, without compromising on quality
- Take the lead in establishing a robust and scalable PQS, and maintaining it
- Ensure all aspects of our production are managed in compliance with our quality policies and procedures
- Elevate the team’s quality understanding, and reinforce an efficient quality culture
- Work with leadership to plan quality strategy to hit our business goals
- Lead and support audits
- Prepare Mytos for future commercial batch release

You bring:

- Significant QA experience (>5 years) in a GxP environment, ideally in ATMPs, biologics, or cell therapy
- Strong understanding of MHRA and EU GMP, with hands-on experience preparing for inspections
- Experience with PQS systems covering document control, deviations, CAPA, change control, validation, and training
- You meet MHRA requirements to be a Quality Controller on the MIA(IMP) license
- Experience in auditing and being audited
- Comfortable working in a fast paced environment
- Excellent written and verbal communication skills

Nice to have:

- Experience in the release of ATMP products - ideally PSC-derived Cell Therapies
- Have previously setup a PQS from scratch, and obtained a MIA(IMP) license
- Experience setting up electronic systems such as eQMS (MasterControl) and electronic Batch Records/Manufacturing execution systems
- Knowledge and experience with FDA regulations

Salary and Benefits:

- Competitive salary with stock options
- Lunch covered daily
- Collaborative team environment with very high potential to learn new skills
- 24 days holiday (excluding bank holidays)
- Pension

We’re building a team that enjoys moving fast, strives for continuous improvement through learning from mistakes and is passionate about work that contributes to solving real world problems.

Join us if you want a fast-paced environment, where you’re empowered to make decisions and do the best work of your career.

## About Mytos

## Company Overview
- **One-liner**: Mytos is building the world’s first fully automated cell manufacturing platform to scale regenerative medicines from clinical trials to millions of patients at low cost.
- **Entity Type**: Private (Series A, $24M+ total funding)
- **Headquarters**: London, United Kingdom
- **Founded**: 2016
- **Founders**: Ali Afshar (CEO) and Ignacio Willats

## Core Business
- **Primary industry**: Biotechnology / Regenerative Medicine / Automated Cell Therapy Manufacturing
- **Target customers**: Clinical-stage cell therapy companies (B2B, Enterprise CDMO), large pharma R&D groups
- **Mission**: To scale regenerative medicines to millions of patients by automating the production of stem cell-derived therapies

## Products & Services
- **iDEM™ Platform**: Proprietary automated cell culture system that uses standard 2D T-flasks to seamlessly port manual protocols into closed, scalable automation without compromising biology. Reduces labour per batch by up to 10x and cleanroom footprint per batch by another 10x.
- **Mytos CDMO**: A fully automated contract development and manufacturing organization (CDMO) powered by iDEM technology. Site 1 is housed within the Cell and Gene Therapy Catapult’s 80,000 sqft facility in Stevenage, UK. Offers end-to-end manufacturing services including Process & Analytical Development, Regulatory Support, and batch production with up to 50% lower batch costs compared to manual CDMOs.

## Market Standing
- **Valuation**: Not publicly disclosed
- **Key Metric**: Total funding of over $24M (Series A led by Buckley Ventures in November 2023; prior rounds include Y Combinator, IQ Capital, and TBD Angels)
- **Notable Investors/Partners**: Y Combinator, Buckley Ventures, IQ Capital; founders/execs from Wayve, Dropbox, Segment, Mercury, Sana, BMS, Revolut; partnerships with Pluristyx, NOVADIP Biosciences, StemSight, and Rinri Therapeutics
- **Growth Signals**: Headcount of ~27 employees (+11.6% YoY); announced three cell therapy manufacturing deals in September 2025; launched automated CDMO in October 2025; first in-patient dosing targeted for 2027; 5 active job postings; strong LinkedIn follower growth (+39.4% yearly)

## Competitive Advantages
- **Biology-preserving automation**: Uses the same 2D T-flask format as manual culture, meaning no need to re-engineer existing protocols — a major barrier to adoption for competing solutions.
- **Fleet architecture**: Unlike large robotic-arm solutions, the iDEM fleet has no single point of failure, increasing reliability for clinical/commercial production.
- **Cost leadership**: Claims up to 50% lower batch costs vs. manual CDMOs and 10x labour reduction, making therapies economically viable at scale.
- **End-to-end CDMO model**: Integrates process development, regulatory support, and manufacturing under one roof, reducing tech transfer delays.

## Strategic Focus
- **Scale the CDMO**: Expand global manufacturing sites beyond the UK (plans in place for a series of global sites).
- **Clinical validation**: Move from R&D partnerships to clinical-stage manufacturing, with cells produced on iDEM entering patients by 2027.
- **Partnership pipeline**: Continue signing deals across multiple therapeutic areas (Parkinson’s, blindness, bone repair, hearing loss) to diversify revenue and de-risk technology.
- **Hiring for growth**: Actively recruiting across engineering, quality, and scientific leadership to support CDMO ramp-up.

## Why Work Here
- **Mission-driven impact**: Directly work on curing Parkinson’s, blindness, and spinal cord injuries at scale — a rare combination of deep tech and patient impact.
- **Culture & team**: Rated 4.5/5 on employer review platforms (Culture: 4.4, Career: 4.6). Team includes engineers from Dyson, Autodesk, and Matic Robots alongside Nature-published scientists.
- **Work location**: On-site in London (HQ at 80 Wood Lane) with additional offices in Newark, California and Billingstad, Norway.
- **Growth opportunity**: Early-stage company (27 people) with clear trajectory to clinical manufacturing — offers outsized ownership and impact for early hires.
- **Perks & environment**: Fast-paced startup environment; cross-disciplinary collaboration between hardware, software, and biology teams; close ties to Y Combinator and top-tier biotech investors.

## Sources
1. [mytos.bio](https://www.mytos.bio/)
2. [mytos.bio/about](https://www.mytos.bio/about)
3. [mytos.bio/team](https://www.mytos.bio/team)
4. [jobs.lever.co/mytos](https://jobs.lever.co/mytos)
5. [linkedin.com/company/mytosbio](https://linkedin.com/company/mytosbio)

## Other roles at Mytos

- [Manufacturing Lead (Hardware)](https://feeny.ai/job/manufacturing-lead-hardware-mytos-london-hece9emszmy3) — London, United Kingdom
- [Principal Scientist (PD/MSAT)](https://feeny.ai/job/principal-scientist-pd-msat-mytos-london-k1sg669m78rx) — London, United Kingdom
- [Chief of Staff](https://feeny.ai/job/chief-of-staff-mytos-london-hzjngkgttykk) — London, United Kingdom
- [Junior Mechanical Engineer (Summer 2026)](https://feeny.ai/job/junior-mechanical-engineer-summer-2026-mytos-london-czy4dsyhwkpr) — London, United Kingdom
- [Senior Mechanical Engineer](https://feeny.ai/job/senior-mechanical-engineer-mytos-london-41kr09a8t7xc) — London, United Kingdom
- [Junior/Mid Software Engineer](https://feeny.ai/job/junior-mid-software-engineer-mytos-london-z5vvnb9pcger) — London, United Kingdom
- [Senior Product Designer](https://feeny.ai/job/senior-product-designer-mytos-london-kzjj94dtnkjd) — London, United Kingdom
- [General Opportunity](https://feeny.ai/job/general-opportunity-mytos-london-wb9h4jkeb87k) — London, United Kingdom
- [Engineering Technician](https://feeny.ai/job/engineering-technician-mytos-london-pvheyvc2nkjj) — London, United Kingdom